Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Sarclisa Now Approved for Relapsed or Refractory Multiple Myeloma

June 2021 Vol 7 No 3

In March 2021, the FDA accelerated the approval of a new indication for Sarclisa (isatuximab-irfc; from sanofi-aventis), a CD38-directed antibody, in combination with Kyprolis and dexamethasone, for the treatment of adults with relapsed (coming back) or refractory multiple myeloma who have received 1 to 3 previous therapies.

Sarclisa was initially approved by the FDA in 2020, in combination with Pomalyst and dexamethasone, for adults with relapsed or refractory multiple myeloma who have received 2 or more therapies, including Revlimid and a proteasome inhibitor (such as Velcade).

The FDA approval of Sarclisa plus Kyprolis and dexamethasone was based on a multicenter, multinational, randomized, open-label, 2-arm, phase 3 clinical trial of patients with relapsed or refractory multiple myeloma who had previously received 1 to 3 lines of therapy. The study included 302 patients who were assigned to receive either Sarclisa plus Kyprolis and dexamethasone or Kyprolis and dexamethasone alone.

The time of survival without disease progression was not reached (meaning patients are still responding to therapy) in those who received Sarclisa plus Kyprolis and dexamethasone versus 20 months in patients who received Kyprolis and dexamethasone alone. This amounts to a 45% risk reduction of disease progression or death with the addition of Sarclisa to the treatment regimen.

The most common side effects with Sarclisa plus Kyprolis and dexamethasone were upper respiratory tract infection, infusion-related reactions, fatigue, hypertension, diarrhea, pneumonia, dyspnea, insomnia, bronchitis, cough, and back pain.

Recommended For You